Jump Financial’s ARS Pharmaceuticals SPRY Stock Holding History

Jump Financial’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-111,900	Closed	-$750K	–	2232
2023 Q2	$750K	Buy	111,900 +73,810	+194%	+$493K	0.03%	828
2023 Q1	$248K	Sell	38,090 -1,987	-5%	-$15.3K	0.01%	1210
2022 Q4	$342K	Buy	+40,077	New	+$260K	0.02%	967
2022 Q1	–	Sell	-37,800	Closed	-$252K	–	1888
2021 Q4	$252K	Buy	37,800 +5,300	+16%	+$43.1K	0.02%	986
2021 Q3	$324K	Buy	+32,500	New	+$801K	0.02%	627

Other funds holding SPRY

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

CST

Charles Schwab Trust Henderson, Nevada $1.79B AUM 17.47% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Jump Financial's SPRY Position: Q3 2023 in Review

Jump Financial sold out of ARS Pharmaceuticals (SPRY) in Q3 2023, closing a stake of 111,900 shares — an estimated $750K sold.

Jump Financial first reported a position in SPRY in Q3 2021 and held it in 5 quarters. The position peaked at $750K in Q2 2023. 97 funds tracked by Wall St. Rank hold SPRY as of Q3 2023.

Jump Financial reported no remaining ARS Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Jump Financial sold 111,900 ARS Pharmaceuticals shares in Q3 2023, an estimated $750K.
Jump Financial first reported a position in ARS Pharmaceuticals in Q3 2021 and held it in 5 quarters.
Jump Financial's ARS Pharmaceuticals position peaked at $750K in Q2 2023.
97 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2023.

Based on Jump Financial's 13F filing for Q3 2023, filed 7 Nov 2023.